Contemporary Characteristics of Penile Cancer

Squamous Cell Carcinoma of the Penis Clinical Trial

Official title:

Contemporary Characteristics of Penile Carcinoma: at M.D. Anderson Cancer Center, and Harris Health System and Katy, Sugar Land, the Woodlands and Bay Area Regional Care Centers

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04996849
• Other study ID #: PCR04-0148
• Secondary ID: NCI-2021-07693PC
• Status: Recruiting
• Start date: April 22, 2004
• Est. completion date: December 31, 2026

Study information

• Verified date: May 2024
• Source: M.D. Anderson Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study develops a prospective database of patients who are evaluated and treated for penile cancer. This will facilitate analyzing trends in cancer incidence, risk factors, treatment, complications, and tumor progression. It will also prospectively validate the importance of pathological prognostic factors previously reported and outcome related to contemporary treatment.

Description:

PRIMARY OBJECTIVE:

I. To prospectively collect data on the presenting features, management and outcome of penile carcinoma at M.D. Anderson Cancer Center, and Harris Health System and Katy, Sugar Land, The Woodlands and Bay Area Regional Care Centers.

OUTLINE:

Patients undergo data collection every 6 months for up to 15 years.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1000
• Est. completion date: December 31, 2026
• Est. primary completion date: December 31, 2026
• Accepts healthy volunteers: No
• Gender: Male
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• All diagnosed patients with a primary penile malignancy, including those with squamous carcinoma

Exclusion Criteria:

• No patient meeting the above criteria will be excluded

Related Conditions & MeSH terms

• Carcinoma
• Penile Carcinoma
• Squamous Cell Carcinoma of the Penis

Intervention

Other:
• Data Capture
Data collected
• Questionnaire Administration
Ancillary studies

Locations

Country	Name	City	State
United States	M D Anderson Cancer Center	Houston	Texas

Sponsors (2)

Lead Sponsor	Collaborator
M.D. Anderson Cancer Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prospectively collect data on the presenting features, management and outcome of penile carcinoma	Descriptive statistics will be utilized where applicable to address questions relevant to the study aims.	Up to 15 years

External Links

•   MD Anderson Cancer Center Website